Browsing by Author "Dvořák Josef"
Now showing 1 - 20 of 49
Results Per Page
Sort Options
- ItemAbirateron acetate(Farmakon Press, 2017) Richter Igor; Dvořák Josef
- ItemAssociation of the combined parameters including the frequency of primary cilia, CD8 tumor infiltrating lymphocytes and PD-1 expression with the outcome in intestinal cancer(Zerbinis Medical Publications, 2017) Dvořák Josef; Nikolov DH; Dušek Ladislav; Filipová Alžběta; Richter Igor; Buka D.; Ryska Aleš; Mokrý Jaroslav; Filip Stanislav; Melichar Bohuslav; Buchler Tomáš; Abrahámová Jitka
- ItemAxitinib in the Metastic Treatment Renal Cancer(2017) Richter Igor; Dvořák Josef; Hejzlarová Věra; Bartoš Jiří
- ItemBevacizumab in the treatment of uterine cervix carcinoma(2021) Dvořák Josef; Richter Igor; Prokš Jan; Rozsypalová Aneta; Grimová Jana
- ItemBevacizumab in the treatment of uterine cervix carcinoma(2020) Dvořák Josef
- ItemBirateron in the Therapy of Metastic Castratin Resistant Cardinal Prostate Before Immediately of Chemotherapy(2017) Richter Igor; Dvořák Josef; Bartoš Jiří; Hejzlarová Věra; Barsová Lucie; Forster J.
- ItemCabozantinib treatment &ndash case report(2020) Richter Igor; Dvořák Josef
- ItemCabozantinibin in patient with metastatic renal cell carcinoma with extensive skeletal involment(Farmakon Press, 2019) Richter Igor; Dvořák Josef
- ItemCetuximab in the treatment of metastatic renal cell carcinoma(Panax, 2017) Richter Igor; Dvořák Josef; Škach Jiří; Hromádka Peter
- ItemThe changes of tumour vascular endothelial growth factor expression after neoadjuvant chemoradiation in patients with rectal adenocarcinoma(Termedia Sp. z.o.o., 2017) Buka D.; Dvořák Josef; Sitorová Veronika; Sirák Igor; Vobořil René; Melichar Bohuslav; Richter IgorAim of the study: The aim was to examine the effects of neoadjuvant chemoradiotherapy on VEGF expression in patients with locally advanced rectal cancer. Materials and methods: A total of 53 patients with locally advanced rectal cancer were retrospectively studied. Neoadjuvant treatment comprised external beam radiation (50.4 Gy/28 fractions) with continuous infusion of 5-fluorouracil. Four to 6 weeks after the chemoradiotherapy, the patients underwent surgical resection. Immunohistochemistry was performed to assess VEGF expression in the pretreatment biopsies and in resected specimens. Results: Resection with microscopic residual tumour (R1) was performed in two patients while in the remaining 51 patients radical resection with microscopically negative margins (R0) was possible. Downstaging after preoperative chemoradiotherapy was observed in 34 patients (64%). After chemoradiotherapy 24 patients (45%) had decreased VEGF expression, in 20 patients (38%) there was no change, and in two patients it was not possible to assess the dynamics of VEGF expression due to pathologic complete response after chemoradiotherapy. The five-year overall survival (OS) rate was 56% (95% CI: 43–70%). Although the median OS was 2.5 times shorter in patients who experienced decreased VEGF expression during therapy, this difference did not reach statistical significance. VEGF expression was not significant in Cox regression analysis or log-rank test. VEGF expression decreased after neoadjuvant chemoradiotherapy in most patients with rectal adenocarcinoma examined. This decrease was associated with a trend of inferior prognosis. Conclusions: VEGF expression decreased after neoadjuvant chemoradiotherapy in most patients examined. This decrease was associated with a trend of inferior prognosis.
- ItemCobimetinib-progress in the treatment of melanoma(Svoboda, 2017) Dvořák Josef; Richter Igor; Buka D.; Abrahámová Jitka
- ItemCurrent treatment options for metastatic castar-resistant prostate cancer(Current Media s.r.o, 2018) Rozsypalová Aneta; Dvořák Josef; Richter Igor; Buka D.; Grimová Jana; Matoušková Michaela
- ItemEnzalutamide in Patients Metastic Kastračně Resistant Cartridge Prosthes After Previous Chemotherapy Therapy(2017) Richter Igor; Dvořák Josef; Hejzlarová Věra; Bartoš Jiří
- ItemEnzalutamide in the treatment of metastatic castrationally-resistant prostate cancer following previous chemotherapy(Current Media, 2017) Richter Igor; Dvořák Josef; Hejzlarová V.; Bartoš Jiří
- ItemEnzalutamide in the treatment of metastatic castrationally-resistant prostate cancer following previous chemotherapy(Current Media, 2017) Richter I.; Dvořák Josef; Hejzlarová V.
- ItemEnzalutamide in treatment of metastatic castrate resistant metastatic prostate cancer(Solen, s.r.o., 2019) Richter Igor; Dvořák Josef
- ItemExperience with axitinib treatment in mRCC 2nd line patients(2018) Richter Igor; Dvořák Josef
- ItemExperiences with abiraterone in the treatment of prostate cancer(2020) Richter Igor; Dvořák Josef
- ItemExpression and prognostic significance of programmed death-ligand 1 (PD-L1) in Merkel cell carcinoma(Zerbinis Medical Publications, 2019) Richter Igor; Jirásek Tomáš; Čermáková Eva; Bartoš Jiří; Buchler Tomáš; Dvořák Josef
- ItemExtraction of Liver Conditions in Enzalutamide Treated by Enzalutamide - Causes(2017) Richter Igor; Dvořák Josef; Bartoš Jiří; Forster J.
- «
- 1 (current)
- 2
- 3
- »